

# Daniela Trisciuoglio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5749522/publications.pdf>

Version: 2024-02-01

93  
papers

9,098  
citations

101543

36  
h-index

79698

73  
g-index

98  
all docs

98  
docs citations

98  
times ranked

19817  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. <i>Aging</i> , 2016, 8, 603-619.	3.1	1,014
3	Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus. <i>Cancer Research</i> , 2006, 66, 5549-5554.	0.9	314
4	The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 1086-1093.	8.2	182
5	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. <i>Molecular Pharmacology</i> , 2002, 61, 524-532.	2.3	132
6	Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. <i>Cell Death and Differentiation</i> , 2005, 12, 1429-1438.	11.2	124
7	Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. <i>Oncogene</i> , 2017, 36, 4573-4584.	5.9	123
8	Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. <i>European Journal of Cancer</i> , 2009, 45, 2618-2627.	2.8	121
9	Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1 mediated transcriptional activity. <i>FASEB Journal</i> , 2002, 16, 1453-1455.	0.5	117
10	1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6259-6265.	6.4	102
11	Involvement of PI3K and MAPK Signaling in bcl-2-induced Vascular Endothelial Growth Factor Expression in Melanoma Cells. <i>Molecular Biology of the Cell</i> , 2005, 16, 4153-4162.	2.1	88
12	The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target. <i>Oncotarget</i> , 2016, 7, 55789-55810.	1.8	81
13	BCL-XL overexpression promotes tumor progression-associated properties. <i>Cell Death and Disease</i> , 2017, 8, 3216.	6.3	76
14	Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. <i>Cell Death and Disease</i> , 2018, 9, 996.	6.3	75
15	Bcl-2 Regulates HIF-1 Protein Stabilization in Hypoxic Melanoma Cells via the Molecular Chaperone HSP90. <i>PLoS ONE</i> , 2010, 5, e11772.	2.5	72
16	Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. <i>Journal of Cellular Physiology</i> , 2005, 205, 414-421.	4.1	69
17	Differential Involvement of Vascular Endothelial Growth Factor in the Survival of Hypoxic Colon Cancer Cells. <i>Cancer Research</i> , 2008, 68, 285-291.	0.9	69
18	A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 72.	8.6	68

#	ARTICLE	IF	CITATIONS
19	bcl-2 Induction of Urokinase Plasminogen Activator Receptor Expression in Human Cancer Cells through Sp1 Activation. <i>Journal of Biological Chemistry</i> , 2004, 279, 6737-6745.	3.4	60
20	1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1471-1491.	6.4	60
21	Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. <i>Oncogene</i> , 2003, 22, 8441-8447.	5.9	59
22	Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. <i>Cell Death and Differentiation</i> , 2011, 18, 1024-1035.	11.2	53
23	relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. <i>British Journal of Cancer</i> , 2001, 85, 1914-1921.	6.4	51
24	Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. <i>Molecular Cancer</i> , 2014, 13, 230.	19.2	51
25	Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2 Gene Amplified Breast Cancer Cells. <i>Clinical Cancer Research</i> , 2004, 10, 7747-7756.	7.0	50
26	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 977-983.	2.8	49
27	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. <i>Oncotarget</i> , 2016, 7, 11332-11348.	1.8	49
28	CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells. <i>Clinical Cancer Research</i> , 2012, 18, 475-486.	7.0	47
29	Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma. <i>ELife</i> , 2017, 6, .	6.0	47
30	Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. <i>Oncogene</i> , 2016, 35, 3760-3770.	5.9	43
31	Emerging Role of Histone Acetyltransferase in Stem Cells and Cancer. <i>Stem Cells International</i> , 2018, 2018, 1-11.	2.5	43
32	Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer. <i>Current Medicinal Chemistry</i> , 2015, 22, 2812-2818.	2.4	42
33	Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression. <i>Molecular Cancer Research</i> , 2007, 5, 761-771.	3.4	41
34	Involvement of nuclear factor $\kappa$ B in bcl-xL induced interleukin 8 expression in glioblastoma. <i>Journal of Neurochemistry</i> , 2008, 107, 871-882.	3.9	41
35	LMNA Knock-Down Affects Differentiation and Progression of Human Neuroblastoma Cells. <i>PLoS ONE</i> , 2012, 7, e45513.	2.5	40
36	Induction of Apoptosis in Human Cancer Cells by Candidaspongolide, a Novel Sponge Polyketide. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1233-1246.	6.3	39

#	ARTICLE	IF	CITATIONS
37	Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain. <i>Carcinogenesis</i> , 2017, 38, 579-587.	2.8	39
38	Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy. <i>Cell Death and Disease</i> , 2013, 4, e639-e639.	6.3	38
39	Pyruvium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Like Cells and Reduces Metastases through Effects on Lipid Anabolism. <i>Cancer Research</i> , 2020, 80, 4087-4102.	0.9	36
40	Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. <i>European Journal of Cancer</i> , 2002, 38, 2455-2462.	2.8	32
41	PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. <i>Oncotarget</i> , 2015, 6, 15008-15021.	1.8	32
42	microRNA-378a-5p is a novel positive regulator of melanoma progression. <i>Oncogenesis</i> , 2020, 9, 22.	4.9	30
43	Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages. , 2020, 8, e000489.		30
44	Lonidamine Causes Inhibition of Angiogenesis-Related Endothelial Cell Functions. <i>Neoplasia</i> , 2004, 6, 513-522.	5.3	29
45	Removal of the BH4 Domain from Bcl-2 Protein Triggers an Autophagic Process that Impairs Tumor Growth. <i>Neoplasia</i> , 2013, 15, 315-IN37.	5.3	29
46	The thiazole derivative CPTH6 impairs autophagy. <i>Cell Death and Disease</i> , 2013, 4, e524-e524.	6.3	28
47	<sc>JARID</sc> 1B expression and its function in <sc>DNA</sc> damage repair are tightly regulated by mi<sc>RNA</sc>s in breast cancer. <i>Cancer Science</i> , 2019, 110, 1232-1243.	3.9	25
48	HMGA1/E2F1 axis and NFκB pathways regulate LPS progression and trabectedin resistance. <i>Oncogene</i> , 2018, 37, 5926-5938.	5.9	24
49	BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition. <i>Carcinogenesis</i> , 2013, 34, 2558-2567.	2.8	23
50	miR-211 and MITF modulation by Bcl-2 protein in melanoma cells. <i>Molecular Carcinogenesis</i> , 2016, 55, 2304-2312.	2.7	23
51	Phototoxic effect of fluoroquinolones on two human cell lines. <i>Toxicology in Vitro</i> , 2002, 16, 449-456.	2.4	21
52	Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. <i>Oncogenesis</i> , 2018, 7, 20.	4.9	20
53	Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 278.	8.6	19
54	Small molecules targeted to the microtubule-Hec1 interaction inhibit cancer cell growth through microtubule stabilization. <i>Oncogene</i> , 2018, 37, 231-240.	5.9	18

#	ARTICLE	IF	CITATIONS
55	Metabolite profiling of ascidian <i>Styela plicata</i> using LC-MS with multivariate statistical analysis and their antitumor activity. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 614-623.	5.2	17
56	tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells. <i>ChemMedChem</i> , 2013, 8, 800-811.	3.2	16
57	New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy. <i>Drug Discovery Today</i> , 2021, 26, 1126-1135.	6.4	15
58	Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114410.	5.5	15
59	Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity. <i>Journal of Cellular Biochemistry</i> , 2001, 83, 473-483.	2.6	14
60	ZnCl <sub>2</sub> sustains the adriamycin-induced cell death inhibited by high glucose. <i>Cell Death and Disease</i> , 2016, 7, e2280-e2280.	6.3	14
61	Reverse transcriptase inhibitors promote the remodelling of nuclear architecture and induce autophagy in prostate cancer cells. <i>Cancer Letters</i> , 2020, 478, 133-145.	7.2	14
62	The Tubulin Code and Tubulin-Modifying Enzymes in Autophagy and Cancer. <i>Cancers</i> , 2022, 14, 6.	3.7	13
63	Effects of Structurally Different HDAC Inhibitors against <i>Trypanosoma cruzi</i> , <i>Leishmania</i> , and <i>Schistosoma mansoni</i> . <i>ACS Infectious Diseases</i> , 2022, 8, 1356-1366.	3.8	13
64	Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules. <i>Theranostics</i> , 2022, 12, 2427-2444.	10.0	12
65	Affinity purification-mass spectrometry analysis of bcl-2 interactome identified SLIRP as a novel interacting protein. <i>Cell Death and Disease</i> , 2016, 7, e2090-e2090.	6.3	11
66	Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2019, 79, 5612-5625.	0.9	11
67	A novel resveratrol derivative induces mitotic arrest, centrosome fragmentation and cancer cell death by inhibiting $\beta$ -tubulin. <i>Cell Division</i> , 2019, 14, 3.	2.4	9
68	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. <i>Cancers</i> , 2020, 12, 447.	3.7	8
69	PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13122.	4.1	8
70	First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 17031-17050.	6.4	7
71	Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 103.	8.6	5
72	Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma. <i>Cancers</i> , 2021, 13, 3853.	3.7	4

#	ARTICLE	IF	CITATIONS
73	478 Bcl-2 regulates HIF-1a protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90b. <i>European Journal of Cancer, Supplement, 2010, 8, 153.</i>	2.2	2
74	Histone Acetyltransferase Enzymes: From Biological Implications to Most Relevant Inhibitors. <i>Topics in Medicinal Chemistry, 2019, , 93-122.</i>	0.8	1
75	406 The BH4 domain is required for proangiogenic function of bcl-2 protein. <i>European Journal of Cancer, Supplement, 2010, 8, 104.</i>	2.2	0
76	965 Modulation of Autophagic Flux by CPTH6, a Gcn5/pCAF Histone Acetyltransferase Inhibitor With Antitumoral Activity. <i>European Journal of Cancer, 2012, 48, S232.</i>	2.8	0
77	822: The histone acetyltransferases inhibitor CPTH6 preferentially inhibits proliferation of patient-derived lung cancer stem cells in vitro and in vivo. <i>European Journal of Cancer, 2014, 50, S199.</i>	2.8	0
78	284: Evidence of a correlation between bcl-2 protein and miR-211 expression in melanoma cell lines. <i>European Journal of Cancer, 2014, 50, S67.</i>	2.8	0
79	3309 A novel function of Bcl-2 protein: miR-211 regulation in melanoma cells. <i>European Journal of Cancer, 2015, 51, S667.</i>	2.8	0
80	Affinity purification-mass spectrometry analysis of bcl-2 interactome identified SLIRP as a novel interacting protein. <i>European Journal of Cancer, 2016, 61, S94.</i>	2.8	0
81	Role of bcl-2 in cancerâ€™stroma interplay. <i>European Journal of Cancer, 2016, 61, S43.</i>	2.8	0
82	Enhancement of doxorubicin cytotoxicity by histone deacetylase inhibition in human sarcoma cells. <i>European Journal of Cancer, 2016, 61, S111.</i>	2.8	0
83	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. <i>European Journal of Cancer, 2016, 61, S111-S112.</i>	2.8	0
84	HMGA1 is a new biomarker of liposarcoma progression. <i>Annals of Oncology, 2017, 28, v591.</i>	1.2	0
85	Crosstalk between VEGF and Bcl-2 in Tumor Progression and Angiogenesis. , 2004, , 26-39.		0
86	Abstract 1684: Histone deacetylase inhibition enhances Pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer models. , 2014, , .		0
87	Abstract 2324: The histone acetyltransferase inhibitor CPTH6 selectively targets lung cancer stem-like cells. , 2015, , .		0
88	Abstract 4721: Enhancement of doxorubicin cytotoxicity by histone deacetylase inhibition in human sarcoma cells. , 2016, , .		0
89	Abstract 933: Bcl-xL overexpression promotes tumor aggressiveness. , 2017, , .		0
90	Abstract 3699: Histone deacetylase inhibitor ITF2357 induces apoptosis and increases doxorubicin cytotoxicity in preclinical models of human sarcoma. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
91	Abstract 5: The histone acetyltransferase inhibitor CPTH6 impairs tumor angiogenesis acting on both endothelial and cancer cells. , 2018, , .		0
92	Abstract 768: miR-378a-5p acts as a positive regulator of melanoma progression. , 2019, , .		0
93	Abstract 2502: Targeting anti-apoptotic Bcl-2 family for cancer therapy. , 2019, , .		0